Loading News...
Back to Dashboard

Pfizer, Inc. (PFE)

Real-time intraday values

Market Overview

From:
To:
PFE Intraday
No data available
SymbolPFE
IPO DateJun 1, 1972
CEODr. Albert Bourla D.V.M., Ph.D.
Full Time Employees75k
SectorHealthcare
IndustryDrug Manufacturers - General
CountryUnited States
ExchangeNYSE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Performance
PeriodReturn %Value Change
1 Day
-1.35%
-0.41 US$
5 Days
+1.45%
+0.43 US$
1 Month
+6.49%
+1.83 US$
6 Months
+11.15%
+3.01 US$

Analyzing Market with AI

Evaluating the last 30 days of history and fundamental metrics of PFE...

Key Statistics
Market Cap
171.16B
P/E Ratio
39.51
Div Yield
5.73%
52W High
$30.44
52W Low
$23.62

Analyst Consensus

ConsensusBuy
Bullish932.1%
Neutral1760.7%
Bearish27.1%

52W Analyst Price Targets

Min Target
$25.00
Max Target
$36.00
Current$30.01
Avg Target$29.26

Analyst Recommendations

Target Price:$29.26($25.00 - $36.00)
FirmRatingTarget PriceUpside PotentialDate
JP MorganNeutral$30.00-0.03%10/9/2026
Cantor FitzgeraldNeutral$28.00-6.70%10/8/2026
ScotiabankSector Outperform$33.00+9.96%10/6/2026
HSBCHold$30.00-0.03%9/10/2026
GuggenheimBuy$31.00+3.30%8/7/2026
BMO CapitalOutperform$30.00-0.03%7/13/2026
GuggenheimBuy$35.00+16.63%7/13/2026
B of A SecuritiesNeutral$26.00-13.36%7/10/2026
JP MorganNeutral$28.00-6.70%7/8/2026
Cantor FitzgeraldNeutral$27.00-10.03%7/6/2026
Community Thoughts

Share your analysis and sentiment on PFE

Join the community to share your analysis